You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Claims for Patent: 11,872,192

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,872,192

Title:	RET inhibitor for use in treating cancer having a RET alteration
Abstract:	Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Inventor(s):	Erica Evans Raab, Beni B. Wolf
Assignee:	Rigel Pharmaceuticals Inc
Application Number:	US17/377,885
Patent Claims:	1. A method of treating a subject with a rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC), the method comprising orally administering to the subject once daily 200 mg, 300 mg, or 400 mg of Compound 1or a pharmaceutically acceptable salt thereof, wherein Compound 1 is: 2. The method of claim 1, wherein the NSCLC has a RET-gene rearrangement. 3. The method of claim 2, wherein the RET-gene rearrangement is a RET fusion. 4. The method of claim 3, wherein the RET fusion is selected from CLIP1, PIBF1, BCR, FGFRIOP, CEP55, CUX1, MYH13, PTClex9, MPRIP, CCDC6, KIF5B, TRIM33, MBD1, RAB61P2, PRKAR1A, TRIM24, KTN1, HOOK3, TRIM27, AKAP13, FKBP15, ERC1, KIAA1468, KIAA1217, NCOA4, GOLGA5, SPECC1L, TBL1XR1 and ACBD5. 5. The method of claim 3, wherein the RET fusion is selected from CCDC6, KIF5B, TRIM33, TRIM24, and NCOA4. 6. The method of claim 3, wherein the RET fusion is KIF5B. 7. The method of claim 3, wherein the RET fusion is CCDC6. 8. The method of claim 1, wherein the NSCLC is metastatic NSCLC. 9. The method of claim 1, wherein the subject was previously treated with platinum. 10. The method of claim 9, wherein the platinum is selected from cisplatin and carboplatin. 11. The method of claim 1, wherein the subject was previously treated with cabozantinib or vandetanib or both. 12. The method of claim 8, wherein the subject is orally administered 300 mg of Compound 1 once daily. 13. The method of claim 8, wherein the subject is orally administered 400 mg of Compound 1 once daily. 14. The method of claim 1, wherein the subject is orally administered 200 mg of Compound 1 once daily. 15. The method of claim 1, wherein the Compound 1 or a pharmaceutically acceptable salt thereof is administered as one or more solid dosage forms. 16. The method of claim 15, wherein the one or more solid dosage forms are tablets. 17. The method of claim 15, wherein the one or more solid dosage forms are capsules. 18. A method of treating a subject with a metastatic rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC) comprising a RET fusion, the method comprising orally administering to the subject once daily 300 mg of Compound 1 or a pharmaceutically acceptable salt thereof, wherein Compound 1 is: 19. A method of treating a subject with a metastatic rearranged during transfection (RET)-altered non-small cell lung cancer (NSCLC) comprising a RET fusion, the method comprising orally administering to the subject once daily 400 mg of Compound 1 or a pharmaceutically acceptable salt thereof, wherein Compound 1 is:

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.